DrBob, Neurologist, 🧠Mechanic<p>New Review and Meta-Analysis confirms weight gain with discontinuance of <a href="https://vmst.io/tags/Semaglutide" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Semaglutide</span></a> and <a href="https://vmst.io/tags/Tirzepatide" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tirzepatide</span></a> </p><p>Discontinuing GLP1 medications led to a pooled overall mean weight regain of 9.69 kg (or about 22 lbs in patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.</p><p>Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to <a href="https://vmst.io/tags/Obesity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Obesity</span></a>.</p><p><a href="https://vmst.io/tags/wegovy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>wegovy</span></a> <a href="https://vmst.io/tags/ozempic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ozempic</span></a> <a href="https://vmst.io/tags/mounjaro" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>mounjaro</span></a> <a href="https://vmst.io/tags/zepbound" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>zepbound</span></a><br><a href="https://onlinelibrary.wiley.com/doi/10.1111/obr.13929" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">onlinelibrary.wiley.com/doi/10</span><span class="invisible">.1111/obr.13929</span></a></p>